SCHEMBL6921853

SCHEMBL6921853

COCCc1nc2cc(-c3cccc(F)c3)ccc2c(=O)n1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.45
ALDH1A1 P00352 3/20 0.45
CYP1A2 P05177 3/20 0.45
CLK4 Q9HAZ1 2/20 0.45
CYP2C19 P33261 2/20 0.45
GLA P06280 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HDAC6 Q9UBN7 2/20 0.41
PDE10A Q9Y233 1/20 0.40
TNKS2 Q9H2K2 1/20 0.39
USP2 O75604 2/20 0.39
TSHR P16473 2/20 0.39
TGFBR1 P36897 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
HDAC8 Q9BY41 1/20 0.38
SYK P43405 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
KCNA5 P22460 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059535 0.89 CYP3A4 (0.41) CYP3A4ALDH1A1CYP1A2CLK4CYP2C19
SCHEMBL12059512 0.84 BCL2A1 (0.42) CYP3A4ALDH1A1CYP1A2CLK4HDAC6
SCHEMBL2052678 0.84 GRM5 (0.39) CYP3A4ALDH1A1CYP1A2CLK4CYP2C19
SCHEMBL12059534 0.82 PIM1 (0.44) CYP3A4ALDH1A1CYP1A2CLK4HDAC6
SCHEMBL6923028 0.82 PARG (0.42) CYP3A4ALDH1A1CYP1A2CLK4HDAC6
SCHEMBL6920609 0.79 ALDH1A1 (0.47) ALDH1A1HSD17B10KCNH2
SCHEMBL6920977 0.77 HDAC6 (0.44) CYP3A4ALDH1A1HSD17B10HDAC6PDE10A
SCHEMBL6920846 0.76 PARP1 (0.46) PDE10ATNKS2
SCHEMBL6922981 0.76 TNKS2 (0.40) CYP3A4ALDH1A1CYP1A2CLK4CYP2C19
SCHEMBL1161767 0.74 L3MBTL1 (0.44) CYP3A4HDAC6TSHRHDAC8KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP3A4 4447/4885ALDH1A1 1721/4885CYP1A2 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.